PriceTargets.com logo

Rezolute - RZLT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 64.95%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$9.70 As of 12/4/2025 05:00 PM ET
▲ +0.23 (2.43%)

This chart shows the closing price for RZLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rezolute Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RZLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RZLT

Analyst Price Target is $16.00
▲ +64.95% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Rezolute in the last 3 months. The average price target is $16.00, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 64.95% upside from the last price of $9.70.

This chart shows the closing price for RZLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in Rezolute. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2025BTIG ResearchReiterated RatingBuy ➝ Buy$17.00
10/29/2025CitigroupReiterated RatingOutperform ➝ Outperform
10/29/2025JMP SecuritiesSet Target$17.00
10/29/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$9.00 ➝ $17.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/22/2025GuggenheimReiterated RatingBuy ➝ Buy$15.00
9/18/2025Maxim GroupBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
9/18/2025WedbushReiterated RatingOutperform$12.00
9/18/2025BTIG ResearchReiterated RatingBuy ➝ Buy$17.00
9/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00
5/14/2025WedbushReiterated RatingOutperform$12.00
4/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
2/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
2/13/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $9.00
2/10/2025GuggenheimReiterated RatingBuy ➝ Buy
2/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
2/4/2025Craig HallumUpgradeStrong-Buy
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/4/2024WedbushReiterated RatingOutperform$112.00
9/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
9/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00 ➝ $7.00
9/10/2024BTIG ResearchBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
9/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/27/2024GuggenheimInitiated CoverageBuy$11.00
8/6/2024Maxim GroupBoost TargetBuy ➝ Buy$8.00 ➝ $10.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
7/17/2024BTIG ResearchInitiated CoverageBuy$13.00
6/4/2024Craig HallumInitiated CoverageBuy$14.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
4/18/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$7.00
4/18/2024JonestradingInitiated CoverageBuy$10.00
4/9/2024Maxim GroupInitiated CoverageBuy$8.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00
11/14/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $7.00
9/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00
9/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$8.00
6/28/2023Cantor FitzgeraldLower Target$7.00 ➝ $5.00
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
5/15/2023HC WainwrightLower Target$17.00 ➝ $14.00
3/28/2023HC WainwrightReiterated RatingBuy$17.00
2/14/2023HC WainwrightLower TargetBuy$21.00 ➝ $17.00
2/13/2023JMP SecuritiesReiterated RatingMarket Outperform$8.00
9/16/2022JMP SecuritiesReiterated RatingBuy$8.00
9/12/2022Jefferies Financial GroupInitiated CoverageBuy$11.00
8/2/2022Canaccord Genuity GroupReiterated RatingAssumes$17.00
6/15/2022Cantor FitzgeraldInitiated CoverageOverweight$9.00
5/16/2022HC WainwrightReiterated RatingBuy$21.00
3/23/2022Roth CapitalBoost Target$23.00 ➝ $25.00
2/23/2022Roth CapitalSet Target$23.00
11/15/2021JMP SecuritiesLower TargetBuy$30.00 ➝ $18.00
9/17/2021HC WainwrightReiterated RatingBuy$21.00
9/16/2021JMP SecuritiesReiterated RatingBuy$30.00
9/10/2021JMP SecuritiesReiterated RatingBuy$30.00
9/8/2021Roth CapitalInitiated CoverageBuy$21.00
5/26/2021OppenheimerInitiated CoverageOutperform$25.00
5/25/2021HC WainwrightInitiated CoverageBuy$21.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 13 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 12 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 7 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 7 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Rezolute logo
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $9.70
Low: $9.28
High: $9.85

50 Day Range

MA: $9.37
Low: $8.07
High: $10.76

52 Week Range

Now: $9.70
Low: $2.21
High: $11.46

Volume

2,362,645 shs

Average Volume

1,471,023 shs

Market Capitalization

$899.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Rezolute?

The following Wall Street sell-side analysts have issued reports on Rezolute in the last twelve months: BTIG Research, Citigroup Inc., Citizens Jmp, Craig Hallum, Guggenheim, HC Wainwright, JMP Securities, Maxim Group, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for RZLT.

What is the current price target for Rezolute?

0 Wall Street analysts have set twelve-month price targets for Rezolute in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 64.9%. Maxim Group has the highest price target set, predicting RZLT will reach $20.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $12.00 for Rezolute in the next year.
View the latest price targets for RZLT.

What is the current consensus analyst rating for Rezolute?

Rezolute currently has 1 sell rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RZLT.

What other companies compete with Rezolute?

Other companies that are similar to Rezolute include Disc Medicine, Mineralys Therapeutics, Tarsus Pharmaceuticals, Telix Pharmaceuticals and Xenon Pharmaceuticals. Learn More about companies similar to Rezolute.

How do I contact Rezolute's investor relations team?

Rezolute's physical mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The company's listed phone number is (650) 206-4507 and its investor relations email address is [email protected]. The official website for Rezolute is www.rezolutebio.com. Learn More about contacing Rezolute investor relations.